Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
1 hedge funds and large institutions have $2.28M invested in Hepion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
67% less funds holding
Funds holding: 3 → 1 (-2)
69% less capital invested
Capital invested by funds: $7.45M → $2.28M (-$5.17M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$3.11M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
-$2.08M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$27K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$22K |
HEPA Hedge Fund Activity: Q4 2015 in Review
1 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2015, worth a combined $2.28M — down 69% from $7.45M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of HEPA and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was EAM Investors, exiting entirely with an estimated $3.11M sold.
- 1 institutional investor held Hepion Pharmaceuticals (HEPA) as of Q4 2015, down from 3 in Q3 2015.
- Funds reported $2.28M of Hepion Pharmaceuticals stock for Q4 2015, down 69% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q4 2015 and 2 closed out, a net change of -2 holders.
- The largest Hepion Pharmaceuticals seller in Q4 2015 was EAM Investors, an estimated $3.11M sold.
Based on aggregated 13F filings for Q4 2015.